Literature DB >> 3890260

Cardioprotective effects of defibrotide in acute myocardial ischemia in the cat.

R Niada, R Porta, R Pescador, M Mantovani, G Prino.   

Abstract

We investigated the effects of Defibrotide (D), a natural polydeoxyribonucleotide, on acute myocardial ischemia (AMI) in anesthetized cats. A permanent ligature was placed around the left anterior descending coronary artery (LAD) 12-14 mm from its origin. Ventricular fibrillation and death were exceptional and when they occurred the cats were not included in the evaluation. Pretreatment of cats with D, 32 mg Kg-1 h-1, i.v. infusion, maintained throughout the 5 h occlusion period, reduced AMI-ST segment increases and increased the diminished pressure-rate index (PRI). AMI-induced changes in lactate, ATP and CPK in ischemic tissue were prevented by D. PGI2 gave the same results as D. Atenolol prevented the loss of myocardial CPK, but had no favourable effects on lactate and ATP in ischemic tissue. The beneficial effects of D in AMI reported here could be partly attributed to its ability to enhance PGI2 release from vascular walls; D might also relieve ischemia by improvement of local tissue oxygenation, energy supplies and platelet function by its ability to deaggregate platelet clumps.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3890260     DOI: 10.1016/0049-3848(85)90008-8

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

Review 1.  The use of defibrotide in blood and marrow transplantation.

Authors:  Paul G Richardson; Enric Carreras; Massimo Iacobelli; Bijan Nejadnik
Journal:  Blood Adv       Date:  2018-06-26

Review 2.  Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.

Authors:  K J Palmer; K L Goa
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

3.  Defibrotide reduces infarct size in a rabbit model of experimental myocardial ischaemia and reperfusion.

Authors:  C Thiemermann; G R Thomas; J R Vane
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

4.  Defibrotide versus heparin in the prevention of coronary reocclusion after thrombolysis in acute myocardial infarction.

Authors:  M Tubaro; G Mattioli; F Matta; C Cappello; E Natale; R Ricci; P Gerardi; F Milazzotto
Journal:  Cardiovasc Drugs Ther       Date:  1993-11       Impact factor: 3.727

5.  Selective stimulation of coronary vascular PGI2 but not of platelet thromboxane formation by defibrotide in the platelet perfused heart.

Authors:  P Löbel; K Schrör
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.